Success Metrics

Completion Rate
0%(0/1)
Active Trials
0(0%)
Terminated
1(33%)

Phase Distribution

Ph phase_3
3
100%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(1)
Other(2)

Detailed Status

unknown2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

unknown267%
terminated133%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_3

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

NCT02936037
unknownphase_3

Effect of MD1003 in Spinal Progressive Multiple Sclerosis

NCT02220933
unknownphase_3

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis

NCT02220244

Clinical Trials (3)

Showing 3 of 3 trials
NCT02936037Phase 3

Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

Terminated
NCT02220933Phase 3

Effect of MD1003 in Spinal Progressive Multiple Sclerosis

Unknown
NCT02220244Phase 3

Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis

Unknown

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3